Infanrix (Pertussis Toxoid Adsorbed On Aluminium Hydroxide, Pertussis Pertactin Adsorbed On Aluminium Hydroxid)

The active ingredients—pertussis toxoid and pertactin adsorbed on aluminium hydroxide—present key bacterial antigens to the immune system. This stimulates B‑cells and T‑cells to produce specific antibodies and cellular responses, creating long‑lasting protection against pertussis infection.

The dosage and schedule of Infanrix are determined by the prescribing clinician and follow national immunisation guidelines. Typically, the vaccine is given as a series of intramuscular injections at specific ages, but the exact regimen should be set by a qualified health professional.

Infanrix is generally not administered to pregnant women; instead, maternal pertussis vaccination is performed with a different formulation. Breastfeeding mothers may receive the vaccine if indicated for their child, but they should discuss any concerns with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Infanrix contains both pertussis toxoid and pertactin antigens, offering a broad immune response. Compared with vaccines that contain only toxoid, Infanrix may provide enhanced protection, especially in regions where pertactin‑deficient strains are prevalent. Clinical choice depends on local guidelines and availability.

Infanrix must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Proper cold‑chain management is essential to maintain vaccine potency until administration.

Infanrix is given by intramuscular injection, usually into the anterolateral thigh in infants and young children. The injection is performed by a qualified healthcare professional using aseptic technique, following the recommended schedule for primary and booster doses.

The most serious adverse events reported with Infanrix include severe allergic reactions such as anaphylaxis, high‑grade fever, seizures, and rare neurological conditions like Guillain‑Barré syndrome. Any signs of a serious reaction require immediate medical evaluation.

Infanrix should not be given to individuals with a known severe allergy to any vaccine component, including aluminium hydroxide, or to infants younger than 6 weeks. Persons with a history of severe vaccine‑related reactions should consult a healthcare professional before vaccination.